Eisai Breaks Ground for Parenteral Drug Facility

November 16, 2006
Patricia Van Arnum

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

ePT--the Electronic Newsletter of Pharmaceutical Technology

Research Triangle Park, NC (Nov. 13)-Eisai Inc. broke ground here for a new pharmaceutical production and formulation research and development facility for parenteral oncology drugs.

Research Triangle Park, NC (Nov. 13)-Eisai Inc. (Teaneck, NJ, www.eisai.com) broke ground here for a new pharmaceutical production and formulation research and development facility for parenteral oncology drugs.

Eisai will invest $90 million in the 65,000-ft2 facility, which will encompass aseptic processing suites, laboratories, and other support functions. In addition, a separate $15-million central utilities building is planned to supply power, steam, chilled water, and compressed air to existing and new operations. Facility completion is expected in three years with operations beginning in 2009.

The new facility will complement the company’s existing 190,000-ft2 structure. That facility manufactures “Aricept” (donepezil hydrochloride) and “Aciphex” (rabeprazole sodium) tablets and also houses formulation research and development and manufacturing of compounds for use in clinical trials.

Eisai has several oncology drugs in development and recently acquired four oncology-related products from Ligand Pharmaceuticals (San Diego, CA, www.ligand.com).